SCHEMBL883098

SCHEMBL883098

Cc1ccc(C(=O)OC(C(=O)O)[C@H](OC(=O)c2ccc(C)cc2)C(=O)O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.68
TSHR P16473 1/20 0.68
TDP1 Q9NUW8 1/20 0.55
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PKM P14618 1/20 0.49
APEX1 P27695 1/20 0.49
CYP2C19 P33261 1/20 0.49
BLM P54132 1/20 0.49
HSD17B10 Q99714 1/20 0.49
RECQL P46063 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48
CYP2D6 P10635 1/20 0.47
CES2 O00748 2/20 0.46
CES1 P23141 2/20 0.46
LMNA P02545 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
PDCD1 Q15116 1/20 0.46
CD274 Q9NZQ7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72171 1.00 TP53 (0.68) TP53TSHRTDP1ALDH1A1SMN1; SMN2
SCHEMBL938198 1.00 TP53 (0.68) TP53TSHRTDP1ALDH1A1SMN1; SMN2
SCHEMBL57818 1.00 TP53 (0.68) TP53TSHRTDP1ALDH1A1SMN1; SMN2
SCHEMBL29777001 1.00 TP53 (0.68) TP53TSHRTDP1ALDH1A1SMN1; SMN2
SCHEMBL6532887 1.00 TP53 (0.68) TP53TSHRTDP1ALDH1A1SMN1; SMN2
SCHEMBL6309997 1.00 TP53 (0.68) TP53TSHRTDP1ALDH1A1SMN1; SMN2
SCHEMBL72682 1.00 TP53 (0.68) TP53TSHRTDP1ALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL19279013 0.98 TP53 (0.66) TP53TSHRTDP1ALDH1A1SMN1; SMN2
Water SCHEMBL1322822 0.98 TP53 (0.66) TP53TSHRTDP1ALDH1A1SMN1; SMN2
Water SCHEMBL743190 0.98 TP53 (0.66) TP53TSHRTDP1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023239906-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-12-14 WO disclosed
US-20210101897-A1 PROCESS FOR THE SYNTHESIS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6-(3-METHYL-1H-PYRAZOL-4-YL)THIENO[3,2-d]PYRIMIDIN-4(3H)-ONE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-08 US disclosed
EP-3219702-A1 METHOD FOR RESOLUTION OF CITALOPRAM INTERMEDIATE 5-CYANOGEN DIOL Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) 2017-09-20 EP disclosed
WO-2017091453-A1 NOVEL PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS USING HYDROGEN BONDING CATALYSTS MERCK SHARP & DOHME CORP. (US) 2017-06-01 WO disclosed
WO-2012038411-A1 PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-29 WO disclosed
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2012-02-16 US disclosed
US-7872025-B2 Optically active isomers of ketotifen and therapeutically active metabolites thereof BRIDGE PHARMA, INC. (US) 2011-01-18 US disclosed
US-7557128-B2 Optically active isomers of ketotifen and therapeutically active metabolites thereof BRIDGE PHARMA, INC. (US) 2009-07-07 US disclosed
US-20090149502-A1 Optically active isomers of ketotifen and therapeutically active metabolites thereof ABERG A K GUNNAR 2009-06-11 US disclosed
US-20080287498-A1 Having antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of ketotifen ABERG A K GUNNAR 2008-11-20 US disclosed
US-20070105837-A1 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2][2]-benzazepine, method for the production thereof and use thereof in the production of medicaments SANOCHEMIA PHARMAZEUTIKA AG (AT) 2007-05-10 US disclosed
US-20070105837-A1 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2][2]-benzazepine, method for the production thereof and use thereof in the production of medicaments SANOCHEMIA PHARMAZEUTIKA AG (AT) 2007-05-10 US disclosed
US-7141560-B2 Alanine 2,6-dialkoxyphenyl ester derivatives as hypnotics AKZO NOBEL N.V. (NL) 2006-11-28 US disclosed
EP-1373188-B1 ALANINE 2,6-DIALKOXYPHENYL ESTER DERIVATIVES AS HYPNOTICS AKZO NOBEL NV (NL) 2006-06-07 EP disclosed
WO-2006046252-A2 NOVEL DIASTERIOMERIC SALTS OF ATENOLOL AND THEIR USE IN THE PRODUCTION OF OPTICALLY ACTIVE ATENOLOL IPCA LABORATORIES LIMITED (IN) 2006-05-04 WO disclosed
US-20040059109-A1 Alanine 2, 6-dialkoxyphenyl ester derivatives as hypnotics N.V. ORGANON (NL) 2004-03-25 US disclosed
EP-1373188-A1 ALANINE 2,6-DIALKOXYPHENYL ESTER DERIVATIVES AS HYPNOTICS Akzo Nobel N.V. (NL) 2004-01-02 EP disclosed
WO-2002057218-A1 ALANINE 2,6-DIALKOXYPHENYL ESTER DERIVATIVES AS HYPNOTICS AKZO NOBEL N.V. (NL) 2002-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287498-A1 Having antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of ketotifen OPRK1, HRH2, HRH1 TP53 4871/4885TSHR 3378/4885TDP1 4545/4885
US-20090149502-A1 Optically active isomers of ketotifen and therapeutically active metabolites thereof OPRK1, HRH1, HRH2 TP53 4862/4885TSHR 3518/4885TDP1 4783/4885
US-20070105837-A1 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2][2]-benzazepine, method for the production thereof and use thereof in the production of medicaments CYP4B1, CYP4Z1, HTR3C TP53 4882/4885TSHR 2491/4885TDP1 3486/4885
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF ACKR3, KIT, C3AR1 TP53 4311/4885TSHR 3712/4885TDP1 2863/4885
US-20210101897-A1 PROCESS FOR THE SYNTHESIS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6-(3-METHYL-1H-PYRAZOL-4-YL)THIENO[3,2-d]PYRIMIDIN-4(3H)-ONE CDC7, CDK7, CDCA2 TP53 344/4885TSHR 3191/4885TDP1 359/4885
US-20040059109-A1 Alanine 2, 6-dialkoxyphenyl ester derivatives as hypnotics OPRM1, OPRD1, OPRK1 TP53 4879/4885TSHR 668/4885TDP1 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.